Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Cash & Cash Equivalents
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison
600436
600276
000538
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Cash & Cash Equivalents
¥894.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash & Cash Equivalents
¥22.4B
|
CAGR 3-Years
74%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cash & Cash Equivalents
¥1.2B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
0%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash & Cash Equivalents
¥20.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
37%
|
CAGR 10-Years
24%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash & Cash Equivalents
¥14.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
38%
|
CAGR 10-Years
19%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash & Cash Equivalents
¥391.7m
|
CAGR 3-Years
105%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
894.2m
CNY
Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 894.2m CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
17%
Over the last year, the Cash & Cash Equivalents growth was -51%. The average annual Cash & Cash Equivalents growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been -16% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
